br In summary we propose that mLOY has two sides
In summary, we propose that mLOY has two sides. Natural mLOY reduces lung cancer risk and predicts a better prognosis, although its effects can be abolished by aberrant loss of chromosome Y caused by environmental risk factors. This finding is of great clinical importance for risk stratification and has implications for the pre-vention of lung cancer.
National Program for Support of Top-notch Young Pro-fessionals from the Organization Department of the CPC Central Committee, Jiangsu Specially Appointed Profes-sor project, Innovation of Graduate Student Training Project in Jiangsu Province (grants KYCX17_1260 and KYZZ15_0268), Priority Academic Program for the Development of Jiangsu Higher Education Institutions [Public Health and Preventive Medicine], and Top-Notch Academic Programs Project of Jiangsu Higher Education Institutions (grant PPZY2015A067). The authors wish to thank all the study participants, research staff, and stu-dents who participated in this work.
Note: To access the supplementary material accompa-nying this article, visit the online version of the Journal of Thoracic Oncology at www.jto.org and at https://doi. org/10.1016/j.jtho.2018.09.013.
References 1. Jacobs PA, Brunton M, Court Brown WM, Doll R, Goldstein H. Change of human chromosome count distribution with age: evidence for a sex differences. Nature. 1963;197:1080–1081. 2. Herens C, Brasseur E, Jamar M, Vierset L, Schoenen I, Koulischer L. Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukaemia and preleukaemia. Clin Lab Haemat. 1999;21:17–20. 3. Seton-Rogers S. Genetics: gender-specific factors in cancer susceptibility. Nat Rev Cancer. 2017;17:372.
4. Forsberg LA, Rasi C, Malmqvist N, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46:624–628. 5. Wright DJ, Day FR, Kerrison ND, et al. Genetic variants associated with mosaic Y chromosome loss highlight Epirubicin HCl genes and overlap with cancer susceptibility. Nat Genet. 2017;49:674–679.
13. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estima-tion and bias detection through Egger regression. Int J Epidemiol. 2015;44:512–525.
19. Loss of the Y chromosome from normal and neoplastic bone marrows. United Kingdom Cancer Cytogenetics Group (UKCCG). Genes Chromosomes Cancer. 1992;5: 83–88. 20. Guttenbach M, Koschorz B, Bernthaler U, Grimm T, Schmid M. Sex chromosome loss and aging: in situ hybridization studies on human interphase nuclei. Am J Hum Genet. 1995;57:1143–1150.
Journal of Geriatric Oncology xxx (2019) xxx
Contents lists available at ScienceDirect
Journal of Geriatric Oncology
Association of multidimensional comorbidities with survival, toxicity, and unplanned hospitalizations in older adults with metastatic colorectal cancer treated with chemotherapy
Ki Hyang Kim a,b, Jae Jin Lee b,c, Jongphil Kim d, Jun-Min Zhou d, Fabio Gomes b,e, Marina Sehovic b, Martine Extermann b,
a Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
b Senior Adult Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
c Division of Medical Oncology and Hematology, Department of Internal Medicine, Yonsei Noble Hospital, Seoul, South Korea
d Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
e Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom
Received in revised form 10 January 2019 Accepted 4 February 2019 Available online xxxx
Background: Studies of older patients with colorectal cancer(CRC) have found inconsistent results about the correlation of various comorbidities with overall survival(OS) and treatment tolerance. To refine our understand-ing, we evaluated this correlation using the Cumulative Illness Rating Scale-Geriatric(CIRS-G) and heat maps to identify subgroups with the highest impact.
Methods: We retrospectively reviewed 153 patients aged 65 years and older with stage IV CRC undergoing che-motherapy. We calculated CIRS-G scores, and a Total Risk Score(TRS) derived from a previous heat map study. The association between CIRS-G scores/TRS and OS, unplanned hospitalizations, and chemotoxicity was exam-ined by the Cox proportional hazards model.
Conclusions: In older adults with metastatic CRC, the number of CIRS-G grade 4 comorbidities was associated with worse OS but no specific CIRS-G category was independently associated with OS, unplanned hospitalization, or toxicities.